Reaction
Lymphocytic Hypophysitis reporting signals
As of the last recalculation, Lymphocytic Hypophysitis appears in 273 FAERS reports alongside 8 co-occurring drug terms. The strongest observed disproportionality signal is IPILIMUMAB (PRR 521.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ipilimumab | 142 | 521.6 | 523.3 |
| Nivolumab | 130 | 194.8 | 195.1 |
| Epoprostenol | 7 | 41.8 | 41.8 |
| Atezolizumab | 16 | 33.3 | 33.3 |
| Pembrolizumab | 37 | 30.9 | 30.9 |
| Durvalumab | 8 | 30.9 | 30.9 |
| Pemetrexed | 8 | 29.3 | 29.3 |
| Encorafenib | 3 | 23.3 | 23.4 |